Webb8 maj 2024 · “More than 1.7 million patients have been treated with Injectafer in the US and healthcare providers now have an additional dosing option for adult patients with IDA who may not be appropriate for oral iron or who have non-dialysis dependent CKD.” Injectafer was first approved by the FDA in 2013 as a 1500 mg course of treatment ... WebbVifor Pharma products are present in more than one hundred countries through a unique combination of our commercial operations and collaborations with market-leading partners. Vifor Pharma products are present in more than one hundred countries through a unique combination of our commercial operations.
CONFIRM-HF study demonstrates that Injectafer(r)
Webb20 aug. 2013 · When analyzed by baseline hemoglobin, ESA use and CKD stage, noninferiority of FCM was again demonstrated for all comparisons except baseline hemoglobin levels of ≤9 g/dL and Stage 5 CKD. The mean increases in ferritin, TSAT and serum iron from the baseline to the highest value by Day 56 were also significantly … Webb6 dec. 2024 · The differential effects of the iron formulations on serum phosphate were magnified among patients without CKD but were also detectable among those with CKD (mean difference between groups in change from baseline to week 2, 1.73 mg/dl, 95%CI 1.66–1.80 vs. 1.02 mg/dl, 95%CI 0.90–1.14). Clinical risk factors for hypophosphatemia. hcrhs.org
Injectafer® (ferric carboxymaltose injection) Receives FDA
Webb2 sep. 2014 · 304 stable ambulatory symptomatic patients with chronic heart failure and iron deficiency were randomized 1:1 to treatment with i.v. Injectafer ® /Ferinject ® (n=152 ) or placebo (saline, n=152 ... WebbIron deficiency is an important clinical concern in chronic kidney disease (CKD), giving rise to iron-deficiency anemia and impaired cellular function. Oral supplementation, in … WebbINJECTAFER is an iron replacement product indicated for the treatment of iron deficiency anemia in adult and pediatric patients 1 year or older who have intolerance to oral iron or have unsatisfactory response to oral iron or adult patients who have non-dialysis dependent chronic kidney disease (NDD-CKD). hcrhs naviance